Sagimet BiosciencesSTU:0O2 +1.66%10 Cash Ratio is 19.74 as of Mar. 2026, which is 2% below its 10-year median of 20.15. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,390 Biotechnology companies, Sagimet Biosciences ranks better than 93.24% on this metric.
Sagimet Biosciences has a Cash Ratio of 19.74. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Sagimet Biosciences's Cash Ratio or its related term are showing as below:
STU:0O2'
s Cash Ratio Range Over the Past 10 Years
Min: 3.5 Med: 20.15 Max: 42.95
Current: 19.74
During the past 7 years, Sagimet Biosciences's highest Cash Ratio was 42.95. The lowest was 3.50. And the median was 20.15.
STU:0O2's Cash Ratio is ranked better than 93.24% of 1390
companies
in the Biotechnology industry
Industry Median: 2.93
vs STU:0O2: 19.74
Sagimet Biosciences (STU:0O2) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Sagimet Biosciences Cash Ratio Related Terms
Sagimet Biosciences Cash Ratio Historical Data
* Premium members only.
The historical data trend for Sagimet Biosciences's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0O2 vs EDIT, AUTL, FBRX: Cash Ratio Comparison
For the Biotechnology subindustry, Sagimet Biosciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sagimet Biosciences (STU:0O2) has a Cash Ratio of 19.74 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Sagimet Biosciences and its competitors. This is near median its historical median of 20.15. Over the past decade, Sagimet Biosciences' Cash Ratio has ranged from 3.50 to 42.95. According to the industry distribution chart, Sagimet Biosciences ranks #94 out of 1390 companies in the Biotechnology industry, placing it in the top 6.8%.
Is Sagimet Biosciences' Cash Ratio too high?
Sagimet Biosciences' current Cash Ratio of 19.74 is near median its 10-year median of 20.15. Over the past 10 years, this metric has ranged from a low of 3.50 to a high of 42.95. The Biotechnology industry median Cash Ratio is 2.93. Sagimet Biosciences' value of 19.74 is 573.7% above this industry median. Based on the distribution chart, Sagimet Biosciences ranks #94 out of 1390 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Cash Ratio compare to EDIT and AUTL?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #94 out of 1390 companies for Cash Ratio. This places Sagimet Biosciences in the top 7% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. Sagimet Biosciences' value of 19.74 is 573.7% above this benchmark. Historically, Sagimet Biosciences' own Cash Ratio has ranged from 3.50 to 42.95 over the past decade. While the company's 10-year median is 20.15 vs. the industry median of 2.93, Sagimet Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,390 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sagimet Biosciences's current Cash Ratio of 19.74 is 573.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Sagimet Biosciences and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sagimet Biosciences's current Cash Ratio is 19.74, which is near median its own 10-year median of 20.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Cash Ratio of 19.74. The current Cash Ratio is 19.74, which is near median its 10-year median of 20.15 and 573.7% above the Biotechnology industry median of 2.93. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Cash Ratio is 19.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score
Get the complete analysis for STU:0O2
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 
